Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma
Previous reports suggest benefit of neoadjuvant chemotherapy/chemoradiation treatment for borderline resectable cholangiocarcinoma. This study is a single center prospective phase II study of neoadjuvant chemotherapy with mFOLFOXIRI in patients with borderline resectable cholangiocarcinoma.
Cholangiocarcinoma
DRUG: mFOLFOXIRI
The rate of overall response evaluated by MRI or CT, The rate of response evaluated by MRI or CT according to RECIST 1.1 criteria, Up to 15 weeks
Resectability rate, The rate of patients who can successfully undergo surgery after chemotherapy, Up to 24 weeks|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, every 15 days for approximately 24 weeks
Previous reports suggest benefit of neoadjuvant chemotherapy/chemoradiation treatment for borderline resectable cholangiocarcinoma.

This study is a single center prospective phase II study of neoadjuvant chemotherapy with mFOLFOXIRI in patients with borderline resectable cholangiocarcinoma.

This phase 2 trial was designed to enroll 25 patients with BRCC who were assigned to mFOLFOXIRI neoadjuvant chemotherapy. The primary endpoint was the overall response rate.